Premium
Detection of peptide‐specific cytotoxic T‐lymphocyte precursors used for specific immunotherapy of pancreatic cancer
Author(s) -
Suzuki Nobuaki,
Maeda Yoshiaki,
Tanaka Shoko,
Hida Naoya,
Mine Takashi,
Yamamoto Koutaro,
Oka Masaaki,
Itoh Kyogo
Publication year - 2001
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10145
Subject(s) - ctl* , pancreatic cancer , immunotherapy , cytotoxic t cell , medicine , cancer , peptide , immunology , peripheral blood mononuclear cell , cancer immunotherapy , peptide vaccine , cancer research , antigen , immune system , biology , epitope , cd8 , biochemistry , in vitro
The prognosis of pancreatic cancer is extremely poor with a 5‐year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T‐lymphocyte (CTL) precursors reacting to peptides with vaccine candidates (13 peptides for HLA‐A2 + or ‐A24 + patients, respectively) were detectable in the prevaccination peripheral blood mononuclear cells (PBMCs) of 15 pancreatic cancer patients. Peptide‐specific CTL precursors were detectable in the majority (11 of 15, 73%) of patients, with a mean positive number of 1.5 peptides (ranging from 0–5 peptides) per patient. Positive peptide profiles varied among patients. These results may provide a scientific basis for a new kind of cancer immunotherapy, namely, a CTL precursor‐oriented peptide vaccine, for pancreatic cancer patients. © 2001 Wiley‐Liss, Inc.